Literature DB >> 19945622

Dystrophic epidermolysis bullosa: pathogenesis and clinical features.

Leena Bruckner-Tuderman1.   

Abstract

Dystrophic epidermolysis bullosa (DEB) is relatively well understood. Potential therapies are in development. This article describes the pathogenesis and clinical features of DEB. It also describes therapeutic options and the future of molecular therapies.

Entities:  

Mesh：

Year:  2010        PMID： 19945622     DOI： 10.1016/j.det.2009.10.020

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN： 0733-8635            Impact factor:   3.478


  37 in total

1.  Folding delay and structural perturbations caused by type IV collagen natural interruptions and nearby Gly missense mutations.

Authors:  Eileen S Hwang; Barbara Brodsky
Journal:  J Biol Chem       Date:  2011-12-16       Impact factor: 5.157

Review 2.  Topical Collagen-Based Biomaterials for Chronic Wounds: Rationale and Clinical Application.

Authors:  Lisa J Gould
Journal:  Adv Wound Care (New Rochelle)       Date:  2016-01-01       Impact factor: 4.730

Review 3.  From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.

Authors:  Beau R Webber; Jakub Tolar
Journal:  Mol Ther       Date:  2015-03-24       Impact factor: 11.454

4.  Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy.

Authors:  Olivier Bornert; Tobias Kühl; Jeroen Bremer; Peter C van den Akker; Anna Mg Pasmooij; Alexander Nyström
Journal:  Mol Ther       Date:  2016-05-09       Impact factor: 11.454

5.  Dental and Anaesthetic Challenges in a Patient with Dystrophic Epidermolysis Bullosa.

Authors:  Ali Al-Abadi; Salah A Al-Azri; Abdulaziz Bakathir; Yusra Al-Riyami
Journal:  Sultan Qaboos Univ Med J       Date:  2016-11-30

6.  Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model.

Authors:  Wenbo Wu; Zhiwei Lu; Fei Li; Wenjie Wang; Nannan Qian; Jinzhi Duan; Yu Zhang; Fengchao Wang; Ting Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

Review 7.  Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.

Authors:  Christopher Perdoni; Mark J Osborn; Jakub Tolar
Journal:  Transl Res       Date:  2015-05-27       Impact factor: 7.012

8.  Treatment of feet deformities in epidermolysis bullosa.

Authors:  Marcelo Back Sternick; Pierina Kaneno Ishida Formentini; Gustavo Moreira Costa de Souza; Eduardo Cembranelli Teixeira; Ildeu Afonso de Almeida Filho; Sérgio Moreira da Costa
Journal:  Int Orthop       Date:  2016-02-22       Impact factor: 3.075

Review 9.  Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix.

Authors:  Jakub Tolar; John E Wagner
Journal:  Lancet       Date:  2013-10-05       Impact factor: 79.321

10.  Collagen VII plays a dual role in wound healing.

Authors:  Alexander Nyström; Daniela Velati; Venugopal R Mittapalli; Anja Fritsch; Johannes S Kern; Leena Bruckner-Tuderman
Journal:  J Clin Invest       Date:  2013-07-08       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.